BMY
A little more BMS in the basket
Krilogy Financial LLC just raised its Bristol Myers Squibb position by 61.7%, ending up with 73,468 shares worth roughly $4.01 million. That’s the kind of move that doesn’t set off fireworks, but it does tell you a real-money manager decided BMS deserved a bigger seat at the table.
Why you should care
When institutions add to a name like Bristol Myers Squibb, they’re usually betting on the “grown-up” stuff: cash generation, dividend reliability, and a business that doesn’t need vibes to survive. In BMS’ case, the company is still juggling the usual pharma mix of patents, pipeline drama, and analyst second-guessing — but buyers seem willing to keep nibbling.
The rest of the picture
The article also flagged a few other things that matter more than a random portfolio tweak:
- BMS missed quarterly EPS estimates at $1.26 versus $1.65 expected
- Revenue came in ahead of estimates at $12.50 billion
- Management guided FY2026 EPS to $6.05–$6.35
- The company declared a quarterly dividend of $0.63 per share, with a 4.2% annualized yield
Big picture
So no, this isn’t a moonshot catalyst. But it does reinforce the classic BMS story: a big pharma cash machine with income appeal, modest growth expectations, and enough institutional interest to keep the stock from feeling ignored.